ARWR Stock — Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. (ARWR)

Updated October 16, 2026.

ARWR is a Stock. Total return is -98.1% over the past 32.8 years, 2934.6 points behind SPY at 2836.5%.

Arrowhead Pharmaceuticals develops RNA interference-based medicines targeting intractable diseases, with a pipeline of investigational therapeutics in Phase 1 through Phase 3 clinical trials addressing conditions including metabolic and genetic disorders; the company operates through collaborations with major pharmaceutical partners including Takeda, Amgen, and GlaxoSmithKline. The company does not currently have an established distribution schedule. This security appeals to investors seeking exposure to clinical-stage biotechnology with a focus on RNA-based drug development rather than current income.

ARWR performance versus SPY

Price and return data through 2026-10-16.

Total return is -98.1% over the past 32.8 years, 2934.6 points behind SPY at 2836.5%. Over the past year its total return — price change plus distributions reinvested — is 43.4%. Its deepest 1-year drawdown was 37.6%.

ARWR key facts

Asset type

Stock

Asset class

Equity

Inception date

12/16/1993

Distribution frequency

None

Last close

$55.90 (as of 2026-10-16)

Market cap

$7,896,124,705

Average volume

1772723.0

Beta

1.303

Payout ratio

0.0%

Forward P/E

111.1111

EPS

$-2.28

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ARWR risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 37.6%.

Who may consider ARWR — and who may not

It is a weaker fit for investors who need monthly cash flow (ARWR does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ARWR

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions